17-烯丙胺-17-脱甲氧格尔德霉素对胆囊癌细胞的体外化疗增敏作用  

The Synergistic Effect of 17-Allylamino-17-Demethoxy Geldanamycin with Chemotherapeutics on Gallbladder Carcinoma Cells in vitro

作　　者：张涛[1,2] 锁涛[1] 王志军[3] 胡美玉[3] 童赛雄[1] 

机构地区：[1]复旦大学附属中山医院普外科,上海200032 [2]江苏省苏州市市立医院(东区)微创外科 [3]复旦大学附属中山医院实验研究中心,上海200032

出　　处：《中国临床医学》2009年第5期744-746,共3页Chinese Journal of Clinical Medicine

基　　金：复旦大学附属中山医院青年科研启动基金(2005)

摘　　要：目的:研究17-烯丙胺-17-脱甲氧格尔德霉素(17-allylamino-17-demethoxy geldanamycin,17-AAG)在体外对胆囊癌细胞的化疗增敏作用。方法:四甲基偶氮唑盐法检测不同浓度的常用化疗药物和17-AAG对胆囊癌细胞(GBC-SD)生长影响,和低浓度17-AAG对传统药物的化疗增敏作用。结果:细胞毒实验显示17-AAG在体外对胆囊癌细胞有较强的抑制作用。0.1μM和1μM的17-AAG能够增加传统化疗药物对GBC-SD生长的抑制作用,有增效作用。结论:17-AAG可能成为胆囊癌化疗的有效药物及化疗增敏剂。Objective：To study the effect of 17 allylamino 17-demethoxy geldanamycin （17-AAG） on the chemosensitivity of GBC cells in vitro. Methods：diphenyi tetrazolium bromide （MTT） assays were used to investigate. Results.. In MTT assays, 17AAG can inhibit growth of cancer cells sharply. The anti-tumor activity of chemotherapeutics was observed when combined with 17AAG at 1μM and 0.1 μM, which was a very low cytotoxic concentration. The synergistic effects were very significant. Conclusion：The results suggest that 17 AAG may be potent agents to inhibit development and enhance the chemosensitivity of gallbladder carcinoma in the near future.

关 键 词：17-烯丙胺-17-脱甲氧格尔德霉素 胆囊癌 细胞系 化疗 

分 类 号：R735.8[医药卫生—肿瘤]